A Phase 3 interventional study of Octreotide Acetate in Microspheres and Placebo in Diabetic Retinopathy, sponsored by Novartis. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-11-17.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.
815 studies on the registry are indexed under Retinal Diseases; 105 are open to participants now.
This study's enrollment of 312 is above the median of 60 across 500 interventional studies indexed under Retinal Diseases.
Browse Retinal Diseases studies →Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Moderately severe or severe NPDR or mild PDR in at least one eye:
Exclusion Criteria:
Drug: Octreotide Acetate in Microspheres
Drug: Placebo
time to progression of diabetic retinopathy
time to development or progression of macular edema,
time to moderate vision loss
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis